Publication of ALZLIGHT Pilot in The Journal of Prevention of Alzheimers’s Disease

CTAD presentation e1676468904850

Zealand University Hospital, Technical University of Denmark, and OptoCeutics are pleased to announce the publication of our clinical study ALZLIGHT PILOT in The Journal of Prevention of Alzheimer’s Disease, presented at The Clinical Trials on Alzheimer’s Disease conference 2022

The study made by Zealand University Hospital in collaboration with OptoCeutics and DTU investigates a novel approach of neural treatment through non-invasive light temporally modulated at 40 Hz using Invisible Spectral Flicker (ISF), meaning the flickering is calm to the eye but still significantly detectable by the brain. Originally, temporally modulated light has been shown to reduce amyloid-β and tau loads as well as increase visuo-spatial memory in transgenic mice, but now early indications in human trials point towards potential benefits.

Our clinical studies, ALZLIGHT S1 and S2, are randomized, placebo-controlled pilot trials of light-based brain stimulation with 40 Hz invisible spectral flickering light in patients with mild to moderate Alzheimer’s disease. The active treatment in both studies consists of 40 Hz ISF and the placebo setting consists of color and intensity-matched non-flickering white light, thus rendering the placebo mostly indistinguishable from the active providing good blinding of both subjects, caregivers, and study personnel.

The ALZLIGHT S1 and S2 findings demonstrated that 40 Hz brain stimulation with OptoCeutics’s device seems safe to use with very high adherence.

Thus, the findings motivate the transition to further Phase 2/3 randomized controlled trials for the evaluation of the efficacy of this technology in patients with mild-to-moderate Alzheimer’s disease.

The abstract for the poster can be found on page S76 of the 4/2022 Journal of Prevention of Alzheimer’s Disease which can be downloaded here.

For further information, please contact:

Mai Nguyen, CEO OptoCeutics,

Marcus Carstensen, CTO OptoCeutics,

or call +45 50 20 60 71.

Share This

Copy Link to Clipboard